<html>

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=Windows-1254">
<meta name=Generator content="Microsoft Word 10 (filtered)">
<title>BEY�N DAMAR HASTALIKLARINDA TANIMLAR, SINIFLAMA, EPIDEMIYOLOJI VE RISK
FAKT�RLERI </title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h1
	{margin:0cm;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";}
h2
	{margin:0cm;
	margin-bottom:.0001pt;
	text-indent:0cm;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0cm;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	text-decoration:underline;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0cm;
	margin-right:-7.1pt;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	text-decoration:underline;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:0cm;
	margin-right:-7.1pt;
	margin-bottom:0cm;
	margin-left:18.0pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0cm;
	margin-right:-7.1pt;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
ins
	{text-decoration:none;}
span.msoIns
	{text-decoration:underline;}
span.msoDel
	{text-decoration:line-through;
	color:red;}
@page Section1
	{size:612.0pt 792.0pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>

</head>

<body lang=TR>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0cm'><span style='font-family:
"Times New Roman" !msorm'><b><span style='font-size:16.0pt;font-family:Tahoma;
text-transform:uppercase'>BEY�N DAMAR HASTALIKLARINDA Tan�mlar, S�n�flama,
Ep�dem�yoloj� ve R�sk Fakt�rler� </span></b></span></p>

<p class=MsoNormal style='border:none;padding:0cm'><span style='font-family:
"Times New Roman" !msorm'><span style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='border:none;padding:0cm'><span style='font-family:
"Times New Roman" !msorm'><b><span style='font-size:14.0pt;font-family:Tahoma'>O�uzhan
�OBAN</span></b></span></p>

<p class=MsoNormal style='border:none;padding:0cm'><span style='font-family:
"Times New Roman" !msorm'><span style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='border:none;padding:0cm'><span style='font-family:
"Times New Roman" !msorm'><span style='font-size:12.0pt;font-family:Tahoma'>Son
G�ncelle�tirme Tarihi: <b>12.01.2009</b></span></span></p>

</div>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
style='font-size:12.0pt;font-family:Tahoma'>BEY�N DAMAR HASTALIKLARINDA
TANIMLAR VE SINIFLAMA</span></b></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><i><span
style='font-size:12.0pt;font-family:Tahoma'>Beyin damar hastal�klar�</span></i></span><span
style='font-family:"Times New Roman" !msorm'><span style='font-size:12.0pt;
font-family:Tahoma'> (BDH)- <i>serebrovask�ler hastal�klar</i> (SVH)- terimi
beynin bir b�lgesinin ge�ici veya kal�c� olarak, iskemi veya kanama nedeniyle
etkilendi�i ve/veya beyni besleyen damarlar�n patolojik bir s�re� ile do�rudan
tutuldu�u t�m hastal�klar� kapsar (<b>Tablo1</b>).</span></span></p>

<p class=MsoHeading7><span style='font-family:"Times New Roman" !msorm'><span
style='font-family:Tahoma'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=MsoHeading7 style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><b><span
style='font-family:Tahoma;text-decoration:none'>Tablo 1: </span></b></span><span
style='font-family:"Times New Roman" !msorm'><span style='font-family:Tahoma;
text-decoration:none'>Beyin damar hastal�klar�n�n (BDH) klinik s�n�flamas�</span></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:18.0pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=489 valign=top style='width:366.55pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:0cm;text-indent:0cm'><span
  style='font-size:11.0pt;font-family:Tahoma'>A-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Asemptomatik BDH</span></span></span></p>
  </td>
 </tr>
 <tr>
  <td width=489 valign=top style='width:366.55pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:0cm;text-indent:0cm'><span
  style='font-size:11.0pt;font-family:Tahoma'>B-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Fokal beyin disfonksiyonu ile
  giden BDH</span></span></span></p>
  </td>
 </tr>
 <tr>
  <td width=489 valign=top style='width:366.55pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:0cm;text-indent:0cm'><span
  style='font-size:11.0pt;font-family:Tahoma'>1-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Ge�ici iskemik ataklar (G�A)</span></span></span></p>
  </td>
 </tr>
 <tr>
  <td width=489 valign=top style='width:366.55pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:0cm;text-indent:0cm'><span
  style='font-size:11.0pt;font-family:Tahoma'>2-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>�nme</span></span></span></p>
  </td>
 </tr>
 <tr>
  <td width=489 valign=top style='width:366.55pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:72.0pt;text-indent:-72.0pt'><span
  style='font-size:11.0pt;font-family:Tahoma'>a)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
  </span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>�skemik inme (serebral infarkt)</span></span></span></p>
  </td>
 </tr>
 <tr>
  <td width=489 valign=top style='width:366.55pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:72.0pt;text-indent:-72.0pt'><span
  style='font-size:11.0pt;font-family:Tahoma'>b)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
  </span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Kanay�c� inme (beyin kanamas�,
  subaraknoid kanama)</span></span></span></p>
  </td>
 </tr>
 <tr>
  <td width=489 valign=top style='width:366.55pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <h2 style='margin-left:0cm;text-indent:0cm'><span style='font-size:11.0pt;
  font-family:Tahoma'>C-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Vask�ler demans</span></span></span></h2>
  </td>
 </tr>
 <tr>
  <td width=489 valign=top style='width:366.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:0cm;text-indent:0cm'><span
  style='font-size:11.0pt;font-family:Tahoma'>D-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Hipertansif ensefalopati</span></span></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoBodyText><span style='font-family:"Times New Roman" !msorm'><i><span
style='font-family:Tahoma'>Asemptomatik BDH </span></i></span><span
style='font-family:"Times New Roman" !msorm'><span style='font-family:Tahoma'>kategorisi
vask�ler hastal��a ait serebral veya retinal semptomlar� olmayan hastalar�
ifade etmektedir. G�r�nt�leme y�ntemleri ile saptanabilen asemptomatik beyin
infarktlar� veya boyunda beyni sulayan arterlerin asemptomatik� olarak daralma
veya t�kanmalar� buna �rnek olarak verilebilir.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><i><span
style='font-size:12.0pt;font-family:Tahoma'>Ge�ici iskemik ataklar (G�A)-�
transient� iskemik ataklar (T�A)-</span></i></span><span style='font-family:
"Times New Roman" !msorm'><span style='font-size:12.0pt;font-family:Tahoma'>
terimi iskemik k�kenli oldu�u d���n�len, genellikle bir damar alan�na lokalize
edilebilen, k�sa (tan�m gere�i maksimum 24 saat), fokal serebral fonksiyon kayb�
epizodlar�n� ifade eden klinik bir kategoridir. Semptomlar�n k�sa s�rmesi
iskeminin ge�ici olmas�na ba�l� olabildi�i gibi beyinde kal�c� hasar olu�an
hastalarda da semptomlar k�sa bir s�re i�inde gerileyebilir.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>D�nya Sa�l�k �rg�t� tan�mlamas�na
g�re, <i>inme</i>; vask�ler nedenler d���nda g�r�n�r bir neden olmaks�z�n,
fokal serebral fonksiyon kayb�na ait belirti ve bulgular�n h�zla yerle�mesi ile
karakterize klinik bir sendromdur. �nme nedeniyle komaya giren ve subaraknoid
kanama ge�iren hastalarda fonksiyon kayb� global olabilir. Semptomlar tan�m
gere�i 24 saatten uzun s�rer veya �l�mle sonlanabilir. Sendrom a��rl���, 1-2
g�nde tam d�zelme, k�smi d�zelme, maluliyet ve �l�m olas�l�klar�n� i�eren geni�
bir de�i�kenlik g�sterir. Hafif iskemik inmeler ve G�A� etyopatoloji, prognoz
ve tedavi a��lar�ndan� benzer �zellikler ta��rlar. Bu nedenle bu iki klinik
tabloyu birbirinin devam� gibi ele almak daha do�rudur. Hem G�A (24 saatten
k�sa), hem de inme (24 saatten uzun veya �l�m) tan�m�nda anahtar �zellik ani
yerle�en fokal n�rolojik defisit bulgular�n�n varl��� ve bu bulgular�
a��klayacak nonvask�ler alternatif bir patolojinin olmay���d�r. <b>Tablo 2</b>�de
fokal serebral iskemiye i�aret eden n�rolojik ve ok�ler semptomlar; <b>Tablo 3</b>�de
ise tan� kar���kl���na yol a�abilecek, fokal serebral iskemiyi d���nd�rmeyen
nonfokal n�rolojik semptomlar s�ralanm��t�r.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><i><span
style='font-size:12.0pt;font-family:Tahoma'>Vask�ler demans</span></i></span><span
style='font-family:"Times New Roman" !msorm'><span style='font-size:12.0pt;
font-family:Tahoma'>, iskemik veya kanay�c� inme veya iskemik-hipoksik beyin
lezyonlar� sonucu geli�en, g�nl�k ya�am aktivitelerini� bozacak �l��de a��r
kognitif tutulum ile karakterize, kompleks bir hastal�k olarak tan�mlanabilir.
�ok say�da kortikal infarkt, stratejik lokalizasyonlu az say�da infarkt veya
yayg�n- multifokal� subkortikal tutulum sonucu ortaya ��kabilen demans�
sendromunun ayr�nt�lar� kitab�n ba�ka bir b�l�m�nde tart���lacakt�r (Bak�n�z:
Demans b�l�m�).</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><i><span
style='font-size:12.0pt;font-family:Tahoma'>Hipertansif ensefalopati</span></i></span><span
style='font-family:"Times New Roman" !msorm'><span style='font-size:12.0pt;
font-family:Tahoma'> sendromu, s�kl�kla kan bas�nc� iyi kontrol alt�nda olmayan
kronik hipertansiyonlu hastalarda ortaya ��kar. Kan bas�nc�n�n h�zla y�kselmesi
ile birlikte ba�a�r�s�, bilin� bozuklu�u, epileptik n�betler� ve bazen ge�ici
n�rolojik defisitler g�r�l�r.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoHeading7 style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><b><span
style='font-family:Tahoma;text-decoration:none'>Tablo 20.1.2: </span></b></span><span
style='font-family:"Times New Roman" !msorm'><span style='font-family:Tahoma;
text-decoration:none'>Fokal n�rolojik ve ok�ler semptomlar</span></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>A-������� Motor semptomlar </span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>V�cudun bir yar�s�n�n t�m� veya
  bir b�l�m�nde zaaf veya sarsakl�k ( hemiparezi, monoparezi)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>E�zamanl� bilateral zaaf (paraparezi,
  kuadriparezi)*</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Yutma g��l��� (disfaji)*</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Dengesizlik (ataksi)*</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>B-������� Konu�ma/lisan
  bozukluklar�</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Konu�ulan dili anlamakta veya
  ifade etmekte g��l�k (disfazi)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Okumada (disleksi) veya yazmada
  (disgrafi) g��l�k</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Hesap yapmada g��l�k (diskalkuli)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Peltek konu�ma (dizartri)*</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>C-������� Duyusal semptomlar</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>V�cudun bir yar�s�n�n t�m� veya
  bir b�l�m�nde farkl� duyma (hemisensoriyel bozukluk)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>D-������� Viz�el semptomlar</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Bir g�zde� vizyon kayb� (ge�ici
  monook�ler k�rl�k veya �amaurozis fugax�)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>G�rme alan�n�n� yar�s� veya
  �eyre�inde vizyon kayb� ( hemianopsi, kuadrantanopsi)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Bilateral k�rl�k</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>�ift g�rme (diplopi)*</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>E-������� Vestib�ler semptomlar</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>D�nme hissi (vertigo)*</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>F-������� Davran��sal/kognitif
  semptomlar</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Giyinme, sa� tarama, di�
  f�r�alama vb. aktivitelerde g��l�k; mekan dezoryantasyonu; ihmal �neglect�(vizyo-
  spasyal- persept�el disfonksiyon)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Unutkanl�k (amnezi)*</span></span></p>
  </td>
 </tr>
</table>

<p class=MsoBodyText3><span style='font-family:"Times New Roman" !msorm'><span
style='font-family:Tahoma'>* Tek ba��na oldu�unda mutlaka ge�ici fokal serebral
iskemiyi g�stermez.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><b><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></b></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><b><span
style='font-size:12.0pt;font-family:Tahoma'>Tablo 20.1.3: </span></b></span><span
style='font-family:"Times New Roman" !msorm'><span style='font-size:12.0pt;
font-family:Tahoma'>Nonfokal n�rolojik semptomlar</span></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Jeneralize zaaf ve/veya duyusal
  bozukluk</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Bayg�nl�k hissi, sersemlik hissi</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Bilin� kayb� veya de�i�mesi ile
  birlikte� g�z kararmas� veya iki yanl� g�rme bozuklu�u.</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>�drar veya d��k� inkontinans�</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Konf�zyon</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>�zole oldu�unda a�a��daki
  semptomlardan biri *</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>D�nme hissi (vertigo)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Kulak ��nlamas� (tinnitus)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Yutma g��l��� (disfaji)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Peltek konu�ma (dizartri)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>�ift g�rme (diplopi)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=583 valign=top style='width:437.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Denge kayb� (ataksi)</span></span></p>
  </td>
 </tr>
</table>

<p class=MsoBodyText3><span style='font-family:"Times New Roman" !msorm'><span
style='font-family:Tahoma'>* Bu semptomlar, birka�� bir arada bulundu�unda,
veya di�er fokal n�rolojik semptomlarla birlikte oldu�unda fokal serebral
iskemiye i�aret edebilirler.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<h1><span style='font-family:"Times New Roman" !msorm'><span style='font-family:
Tahoma'>�NME EP�DEM�YOLOJ�S�</span></span></h1>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Epidemiyoloji insan topluluklar�nda
hastal�k s�kl�klar�n�n da��l�m� ( mortalite, insidens, prevalans, zaman
i�indeki� de�i�iklikler) ve belirleyicilerinin (haz�rlay�c� etkenler, risk
fakt�rleri) bilimidir. �nme klinik� olarak� tan�mlanm�� bir sendromdur ve beyin
infarkt�, intraserebral kanama (�SK) ve subaraknoid kanama (SAK) gibi farkl� alt
tipleri i�erir. T�m inmeler i�inde beyin infarkt� %80 (%70-85), �SK %15 (%7-15)
ve SAK ise %5 (%2-8) oran�nda g�r�l�r. Epidemiyolojik �al��malar�n, ideal
olarak, hem global olarak inme, hem de alt tipler i�in ayr� ayr� yap�lmas�
gerekir. Ancak topluma dayanan epidemiyolojik �al��malarda g�venilir olarak alt
tip ayr�m� yapmak g��t�r.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>�nme sadece geli�mi� �lkelerde
de�il, t�m d�nyada da koroner kalp hastal��� ve t�m kanserlerin ard�ndan ���nc�
s�kl�kta gelen �l�m nedenidir. ��nme insidensi g�venilir �al��malar�n
yap�labildi�i beyaz pop�lasyonlar�n �o�unda� birbirine yak�nd�r ve ortalama
olarak bir y�lda, her 1000 ki�ide 2 yeni inmenin ortaya ��kt��� hesaplanm��t�r.
Ya�l� pop�lasyonda (45-84 ya�lar) bu� oran binde d�rde ��kmaktad�r. �nme
prevalans� bir toplumda ya�ayan ve inme ge�irmi� olan insanlar�n oran� olarak
tan�mlan�r ve binde alt� civar�ndad�r. �nme mortalitesinde� bat� �lkelerinin
�o�unda ve Japonya�da son 50 y�ld�r s�regelen bir azalma izlenmektedir.
Mortalite azalmas�, baz� �lkelerde 1980�li y�llar�n ortalar�na kadar izlenen
inme insidensindeki azalman�n �tesindedir ve inme a��rl��� ile inmeye ba�l�
olgu �l�m oran�n�n y�llar i�inde azald���n� d���nd�rmektedir.Buna ra�men, gene
y�llar i�inde toplumdaki ya�l� insan oran�ndaki art��a ba�l� olarak inme ve
inmeye ba�l� �l�mlerin mutlak say�s� artmaktad�r.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>�nmenin toplumsal y�k� �ok a��rd�r.
�nmeli hastalar�n %20�si erken d�nemde olmak �zere %30�u bir y�l i�inde
�lmekte, ya�ayanlar�n ��te biri de g�nl�k i�lerinde� ba�kalar�na muhta� olarak
ya�amlar�n� s�rd�rebilmektedirler. B�ylece inme, toplumda ���nc� en s�k �l�m
nedeni olmas�n�n yan� s�ra, eri�kinlerde ilk s�rada gelen maluliyet nedenidir.�
N�rolojik hastal�klar nedeniyle hastaneye yatan olgular�n� yar�s�ndan
fazlas�n�� inmeli hastalar olu�turmaktad�r. N�fusu giderek ya�lanan �lkemizde
de inmenin �ok �nemli ve �nlenebilir bir sa�l�k sorunu oldu�u a��kt�r.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
style='font-size:12.0pt;font-family:Tahoma'>�NME R�SK FAKT�RLER�</span></b></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Bir hastal���n olu�mas�nda�
yatk�nl�k yaratan etkenler risk fakt�r� olarak tan�mlan�r. �nme risk
fakt�rleri; inmenin alt tipi, risk fakt�r�n�n de�i�tirilebilirli�i, ve inme ile
ili�kisinin bilimsel kesinli�i dikkate al�narak s�n�flanabilir. <b>Tablo 4�</b>de�
iskemik inme ile ili�kili risk fakt�rleri� s�ralanm��, izleyen metinde ise�
bunlar�n �nemlileri tart���lm��t�r. �ntraserebral kanama (�SK) ve subaraknoid
kanama (SAK) ile ili�kili risk fakt�rleri ise metnin sonunda ayr�ca
de�erlendirilmi�tir.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoHeading8><span style='font-family:"Times New Roman" !msorm'><b><span
style='font-family:Tahoma;text-decoration:none'>Tablo20.1.4:� </span></b></span><span
style='font-family:"Times New Roman" !msorm'><span style='font-family:Tahoma;
text-decoration:none'>�skemik inme risk fakt�rleri</span></span></p>

<p class=MsoHeading9 style='text-indent:0cm'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:10.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>I-De�i�tirilemeyen risk
  fakt�rleri</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Ya� </span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Cins</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <h2 style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Soyge�mi�te inme veya G�A �yk�s�</span></span></h2>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Irk</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>D���k do�um tart�s�</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;font-family:Tahoma'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>II- �nme ile ili�kisi kesin ve�
  de�i�tirilebilen risk fakt�rleri</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Hipertansiyon</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Kalp hastal�klar�� (atriyal
  fibrilasyon, koroner arter hastal���, kalp yetersizli�i)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Sigara </span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Diyabet</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Y�ksek kan kolesterol� ve lipidler</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Diyet, obezite, fizik inaktivite</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Menopoz sonras� hormon tedavisi</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Orak h�creli anemi</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Asemptomatik karotis stenozu</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;font-family:Tahoma'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><b><span
  style='font-size:11.0pt;font-family:Tahoma'>III- �nme ile ili�kisi veya
  de�i�tirilmesinin etkisi kesin olmayan risk fakt�rleri</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Metabolik sendrom</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Hiperhomosistinemi</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Alkol kullan�m�</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Madde kullan�m�</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Oral kontraseptif kullan�m�</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:2.0cm;text-indent:-20.7pt'><span
  style='font-family:"Times New Roman" !msorm'><span style='font-size:11.0pt;
  font-family:Tahoma'>Hiperkoag�labilite (antikardiyolipin antikoru, lupus
  antikoag�lan�, fakt�r V Leiden mutasyonu, protein C eksikli�i, protein S
  eksikli�i, antitrombin 3 eksikli�i gibi)</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Lipoprotein (a) y�ksekli�i </span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:2.0cm;text-indent:-20.7pt'><span
  style='font-family:"Times New Roman" !msorm'><span style='font-size:11.0pt;
  font-family:Tahoma'>�nflamatuvar s�re�ler (periodontal hastal�k, C pn�moni,
  sitomegalovirus, H. pylori CagA �seropozitifli�i, akut infeksiyonlar, y�ksek
  hs-CRP</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Migren</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=590 valign=top style='width:442.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt'><span style='font-family:"Times New Roman" !msorm'><span
  style='font-size:11.0pt;font-family:Tahoma'>Uyku apnesi</span></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>������������������ </span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Ya� inme ile ilgili en �nemli risk
fakt�r�d�r. �nme ge�irenlerin yakla��k %70�i 65 ya��n �zerindedir. �nme
insidensi 55 ya��ndan sonra her ony�l i�in iki kat artar. �nme insidensi
erkeklerde kad�nlara g�re 1.25 kez fazlad�r. Ama kad�nlar�n ya�am s�resi
erkeklerden uzun oldu�u i�in inme nedenli mutlak �l�m say�s� kad�nlarda daha
y�ksektir. ABD�de en y�ksek inme insidensi ve mortalite h�zlar� siyah �rkta
g�r�l�r. Japon ve �inli�lerde de y�ksek inme (�zellikle �SK ve intrakranyal
ateroskleroz) insidensi bildirilmi�tir. Sosyoekonomik fakt�rler �rka ba�l�
de�i�ikliklerin de�erlendirilmesini� g��le�tirmektedir. Hem anne, hem de baba
taraf�nda soyge�mi�te inme olanlarda y�ksek� inme riski g�sterilmi�tir. </span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Hipertansiyon iskemik inme i�in en
�nemli de�i�tirilebilir risk fakt�r�d�r. Hipertansiyon varl���nda iskemik inme
s�kl��� 4 kat artar. Arter bas�nc� azald�k�a belirli bir alt s�n�r
bulunmaks�z�n inme riski de azalmaktad�r. �nmelerin yakla��k %60��
hipertansiyona ba�lanabilir. Antihipertansif tedavi ile inme riskinin %40 oran�nda
azald��� g�sterilmi�tir. Bu etki her cins ve �rkta, ileri ya�ta ve izole
sistolik hipertansiyonda da ge�erlidir.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>�ok say�da kalp hastal���n�n inme
riskini artt�rd��� g�sterilmi�tir. Bunlar�n aras�nda en �nemli ve tedavi
edilebilir etken atriyal fibrilasyondur (AF). Kardiyoembolik inmelerin yakla��k
yar�s�� AF'li hastalarda� ortaya ��kmaktad�r. AF inme riskini ba��ms�z olarak
3-5 kat artt�r�r. Ba�ta hipertansiyon olmak �zere pek �ok risk fakt�r�n�n
etkisi ya�la azal�rken AF�nin etkisi artarak s�rer. �yle ki 80 ya��n �zerinde
g�r�len her 4 inmeden biri AF�ye ba�lanabilir. Oral antikoag�lan kullan�m� ile
AF�ye ba�l� inmelerin %70�i �nlenebilir.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Diabetes mellitus ateroskleroz
yatk�nl���n� ve hipertansiyon, obezite, hiperlipidemi gibi di�er aterojenik risk
fakt�rlerinin s�kl���n� artt�r�r. Diabet inme riskini erkeklerde 1.8,
kad�nlarda ise 2.2 kez artt�r�r. Daha s�k� glisemi kontrol� ile inme
insidensinin azalmas� m�mk�n olmakla birlikte hen�z kan�tlanm�� de�ildir. Ancak
diabetiklerde kardiyovask�ler hastal�k mutlak riski �ok y�ksektir ve bu durum
antihipertansif ve antilipidemik tedavi kararlar�n� etkiler.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Hiperkolesterolemi koroner kalp
hastal��� i�in �nemli ve de�i�tirilebilir bir risk fakt�r� olmakla birlikte�
iskemik inme s�kl��� ile ili�kisi zay�ft�r. Ama ekstrakranyal karotis
aterosklerozu ile total ve LDL kolesterol�n� pozitif,� HDL kolesterol�n ise
koruyucu etkisi g�sterilmi�tir. Dahas� statin grubu ila�larla yap�lan
�al��malarda, koroner kalp hastal���n�n yan� s�ra iskemik inme insidensinde da
�nemli bir azalma sa�lanabildi�i ispatlanm��t�r.</span></span></p>

<p class=MsoBodyText2><span style='font-family:"Times New Roman" !msorm'><span
style='font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoBodyText2><span style='font-family:"Times New Roman" !msorm'><span
style='font-family:Tahoma'>Sigara i�ilmesi inme riskini yakla��k iki kat
artt�r�r. ��ilen miktar artt�k�a risk de artmaktad�r. Sigaran�n b�rak�lmas� ile
inme riski h�zla azal�r ve 2-4 y�l i�inde normale yakla��r.</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Alkol kullan�m� ile inme aras�nda
�U� veya �J� �eklinde bir ili�ki g�sterilmi�tir. Yani, az miktarda alkol (g�nde
1-2 kadeh �arap e�de�eri) koruyucu etki g�sterirken y�ksek miktarlarda alkol
riski artt�rmaktad�r.</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Orta derecede fizik aktivite
(haftan�n �o�u g�nlerinde� 30-60 dakika h�zl� y�r�y�� e�de�eri) kan bas�nc�n�n
azalmas�, kilo verilmesi, HDL kolesterolde art��, LDL kolesterolde azalma,
ins�lin duyarl���nda art��, glikoz tolerans�nda d�zelme, trombosit
aggregabilitesinde azalma ve sigaran�n b�rak�lmas�n� kolayla�t�rma gibi olumlu
etkilere� sahiptir. Fizik aktivitede art���n, koroner kalp hastal��� s�kl���n�
azaltman�n yan� s�ra, bir �al��maya g�re sadece erkeklerde, ba�ka bir �al��maya
g�re ise her iki cinste inme riskini azaltt��� g�sterilmi�tir. Obezite; kan
bas�nc�nda, glisemide ve aterojenik kan lipidlerinde art��a yol a�abilir ve
baz� �al��malarda ba��ms�z olarak inme insidensi ile ili�kili bulunmu�tur.
Santral obezite (abdominal b�lgede ya� toplanmas�) genel obeziteye g�re
aterojenik� hastal�klar a��s�ndan� daha �nemli olabilir. Sebze, meyve ve
liflerden zengin; ya�, �zellikle de doymu� ya�lardan fakir bir diyet genel
olarak sa�l��� korumak i�in tavsiye edilmektedir.</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Kan homosistein d�zeyi genetik
fakt�rler� ile B6, B12 vitaminleri ve folik asit al�m� taraf�ndan belirlenir.
Y�ksek kan homosisteininin hem aterojenik hem de tromboza meyil yaratan�
etkileri vard�r. Hiperhomosisteinemi varl���nda koroner kalp hastal�klar� ve
iskemik inme s�kl��� artar. B6, B12, ve� folik asit eklenmesi ile kan
homosistein de�erleri d���r�lebilir. Ancak bu giri�im ile iskemik inme veya
miyokard infarkt�s� s�kl���nda azalma hen�z g�sterilmi� de�ildir.</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>G�A ge�irenlerde y�ll�k inme riski
%4 civar�ndad�r. Di�er maj�r risk fakt�rleri i�in gerekli d�zeltmeler
yap�ld�ktan sonra da, G�A hem inme hem de miyokard infarkt�s� i�in anlaml� ve
ba��ms�z bir risk fakt�r�d�r. G�A nedeni olarak y�ksek dereceli� karotis
stenozu bulunmas�, hemisferik semptomlar�n olmas�, yak�n tarihli G�A ge�irmi�
olma ve muhtemelen kre�endo tarz�nda G�A�lar iskemik inme riskini artt�ran
fakt�rlerdir. G�A ge�iren hastalardan� hangilerinin erken d�nemde inme riski
oldu�unun belirlenmesi tetkik ve tedavilerin aciliyeti a��s�ndan �nemlidir.
Baz� klinik verilere dayan�larak d�zenlenen ABCD� skorlama sistemi bu konuda
yard�mc� olabilir. Ya� (<b>A</b>ge) &#8805;60=1 puan; arter bas�nc� (<b>B</b>lood
pressure) sistolik &gt;140 mm Hg veya diastolik &#8805;90 mm Hg=1 puan; klinik
�zellikler (<b>C</b>linical features) [hemiparezi=2 puan, zaaf olmaks�z�n
konu�ma bozuklu�u=1 puan]; semptomlar�n s�resi (<b>D</b>uration) [&#8805;60
dakika=2 puan, 10-59 dakika=1 puan, &lt;10 dakika=0 puan] olmak �zere toplam 6
puanl�k bu skor 7 g�n i�inde inme ge�irme riskini ba�ar�yla �ng�rmektedir. G�A
ku�kusu ile izlenen 378 hastal�k bir kohortta 7 g�nl�k inme riski, puan� 4 ve
daha az olan 274 hastada %0.4; puan� 5 olan 66 hastada %12.1 ve puan� 6 olan 35
hastada %31.4 olarak bulunmu�tur.</span></span></p>

<p class=MsoNormal><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Asemptomatik karotis stenozundan,
boyunda bir �f�r�m duyuldu�unda veya ultrasonografi gibi bir y�ntemle tarama
s�ras�nda ��phelenilebilir. Hemodinamik olarak anlaml� ekstrakranyal karotis
stenozu ile ipsilateral inme oran� y�lda %1-2 civar�ndad�r. Giderek artan veya
daha ileri stenozlarda risk daha y�ksek olabilir.</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Bir�ok risk fakt�r� bir arada
bulundu�unda, risk fakt�rlerinin tek tek d�zeyleri� �ok y�ksek olmasa bile,
inme riski birka� kat y�kselir. �e�itli risk fakt�rleri dikkate al�narak
haz�rlanan tablolardan bir ki�inin kendi ya��n�n ortalamas�na g�re ka� kat
fazla inme riski ta��d��� hesaplanabilir. Bireysel riskin derecesi risk
fakt�rleri ile m�cadelenin �nemini kavramas�na yard�mc� olur ve tedavi
kararlar�n� etkiler.</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Ya�, spontan �SK ile ilgili en
�nemli risk fakt�r�d�r. �SK erkeklerde kad�nlara g�re, ve� siyah �rkta�
beyazlara g�re daha y�ksektir. Asyal� pop�lasyonlarda �ok y�ksek �SH oranlar�
bildirilmi� olmakla birlikte bu �al��malarda �o�unda BT do�rulamas� yoktur.
Hipertansiyon �SK� i�in en g��l� de�i�tirilebilir risk fakt�r�d�r. G�n�m�zde
antihipertansif tedavi �SKdan korunmada kan�tlanm�� tek tedavi t�r�d�r.
�zge�mi�te inme �yk�s�, a��r alkol kullan�m�, kokain, antikoag�lasyon ve
trombolitik tedavinin �SK i�in de�i�tirilebilir risk fakt�rleri olduklar�
g�sterilmi�tir. �ok d���k serum kolesterol� ( total kolesterol &lt;160 mg/dl)
ve sigara i�iminin risk fakt�r� olup olmad�klar�n�n belirlenmesi i�in ba�ka
�al��malara ihtiya� vard�r.</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>SAK��n ya� ile ili�kisi �SK kadar
belirgin de�ildir. �ok iyi bilinmeyen nedenlerle SAK kad�nlarda ve ABD�de
siyahlarda daha s�kt�r. SAK�l� hastalar�n yakla��k %5�inde soyge�mi�te SAK �yk�s�
bulunur. Polikistik b�brek hastal���, aort koarktasyonu, Marfan sendromu,
Ehlers Danlos sendromu, fibrom�sk�ler displazi gibi nadir kollajen ve elastin
hastal�klar�nda y�ksek SAK insidensi g�r�l�r.� SAK i�in en �nemli
de�i�tirilebilir risk fakt�r� sigara i�ilmesidir. Sigaran�n b�rak�lmas� artm��
riski azalt�r ama t�m�yle ortadan kald�rmaz. Bu ili�kinin patogenezi
bilinmemekle birlikte, akci�erlerde makrofajlar taraf�ndan sal�nan proteolitik
enzim aktivitesi, erken ateroskleroz, nikotin kullan�m� ile ge�ici kan bas�nc�
art��� �ne s�r�len spek�lasyonlar aras�ndad�r. Hipertansiyon da sigara kadar
g��l� olmasa da SAK i�in ba��ms�z bir risk fakt�r�d�r. Sigaran�n b�rak�lmas� ve
antihipertansif tedavinin SAK �nlenmesinde etkinli�i kan�tlanm��t�r. A��r alkol
kullan�m�, �strojen kullan�m� gibi olas� di�er risk fakt�rlerinin de�eri kesin
de�ildir.</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><b><span
style='font-size:12.0pt;font-family:Tahoma'>KAYNAKLAR</span></b></span></p>

<p class=MsoNormal style='margin-right:-7.1pt'><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>1-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Special report from the National
Institute of Neurological Disorders and Stroke. Classification of
cerebrovascular diseases III. Stroke 1990; 21:637-676.</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>2-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Warlow CP, van Gijn J, Dennis MS ve
ark. Stroke: Practical Management. Blackwell Publishing, Massachusetts, 2007</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>3-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Roman, GC. Vascular demantia. ��inde:
Fisher M (ed), Clinical Atlas of Cerebrovascular Disorders. Wolfe, London 1994:
13/1-23</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>4-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Wolf PA, D�Agastino. Epidemiology
of stroke. ��inde: Barnett HJM, Mohr JP, Stein BM, Yatsu FM (eds), Stroke:
Pathophysiology, Diagnosis and Management. Churchill Livingstone, New York 1998:
3-28</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>5-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>�Malmgren R, Warlow C, Bamford J,
Sandercock P. Geographical and secular trends in stroke incidence. Lancet�
1987; 2: 1196-2000</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>6-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Warlow CP. Epidemiology of stroke.
Lancet 1998; 352 (suppl 3): 1-4</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>7-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Murray CJ, Lopez AD. Mortality by
cause for eight regions of the world: Global Burden of Disease Study. Lancet
1997; 349: 1269-1276</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>8-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Thom T, Haase N, Rosamond W ve ark.
Heart disease and stroke statistics- 2009 update. A report from the American
Heart Association Statistics Committee and Stroke Statistics Subcommitee.
Circulation 2006;113:85-151</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>9-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span dir=LTR><span style='font-family:"Times New Roman" !msorm'><span
style='font-size:12.0pt;font-family:Tahoma'>Wolf PA. Prevention of Stroke.
Lancet 1998; 352 (supl 3): 15-17</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>10-</span><span dir=LTR><span
style='font-family:"Times New Roman" !msorm'><span style='font-size:12.0pt;
font-family:Tahoma'>Goldstein LB, Adams R, Alberts MJ ve ark. Primary
prevention of ischemic stroke: a ��guideline from the American Heart
Association/American Stroke Association Stroke Council. Stroke 2006; 37: 1583-1633</span></span></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-7.1pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
style='font-size:12.0pt;font-family:Tahoma'>11-</span><span dir=LTR><span
style='font-family:"Times New Roman" !msorm'><span style='font-size:12.0pt;
font-family:Tahoma'>Rothwell PM, Giles MF, Flossman E ve ark. A simple score
(ABCD) to identify individuals at high early risk of stroke after transient
ischemic attack. Lancet 2005; 366:29-36</span></span></span></p>

</div>

</body>

</html>
